ReviewClinical & experimental metastasis2016
Anti-angiogenic alternatives to VEGF blockade.
Review in Clinical & experimental metastasis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Leptin Promotes Vasculogenic Mimicry in Breast Cancer Cells by Regulating Aquaporin-1.International journal of molecular sciences · 2024Article
- Review
- Identification of kinases activated by multiple pro-angiogenic growth factors.Frontiers in pharmacology · 2022Article
- Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021Review
- miR-27b promotes angiogenesis and skin repair in scalded rats through regulating VEGF-C expression.Lasers in medical science · 2020Article
- Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.Journal of experimental & clinical cancer research : CR · 2020Article
- Structure-Activity Relationship of RGD-Containing Cyclic Octapeptide and αvβ3 Integrin Allows for Rapid Identification of a New Peptide Antagonist.International journal of molecular sciences · 2020Article
- Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Journal of advanced research · 2017Review
- Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors.International journal of oncology · 2017Article
- Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.Cancer science · 2017Article
- The Pleiotropic Role of L1CAM in Tumor Vasculature.International journal of molecular sciences · 2017Review
- Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in mouse cornea.International journal of ophthalmology · 2017Article
- Natural products against cancer angiogenesis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Celastrol and Its Role in Controlling Chronic Diseases.Advances in experimental medicine and biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.